“๐๐ฎ๐๐ ๐ ๐ ๐ฆ๐๐ง ๐๐ฒ ๐ก๐ข๐ฌ ๐ช๐ฎ๐๐ฌ๐ญ๐ข๐จ๐ง๐ฌ ๐ซ๐๐ญ๐ก๐๐ซ ๐ญ๐ก๐๐ง ๐๐ฒ ๐ก๐ข๐ฌ ๐๐ง๐ฌ๐ฐ๐๐ซ๐ฌ.”
– ๐๐จ๐ฅ๐ญ๐๐ข๐ซ๐ย ย ย So hereโs my question: Should a national policy treat perfectly healthy, โat riskโ people for Alzheimerโs before they show a single symptom?
Iโve spent the last several months researching and writing exactly that โ a new national prophylaxis framework for Alzheimerโs prevention. Not early detection. Prevention before onset. [Spoiler alert: in June I will send the 1500-word policy proposal to Health Affairs]
The uncomfortable reality (why this is not academic)
Most healthcare policy waits for a diagnosis. My research flips the model: identify genetic, biomarker, or lifestyle-based risk in healthy individuals, then intervene with drugs, protocols, or monitoring.
The upside is obvious โ delaying or stopping Alzheimerโs entirely. The downside is less discussed: labeling healthy people as โpre-patients,โ potential over-medicalization, and a massive shift in who pays for what.
Whether you love or hate the idea, itโs coming. And that changes your industry.
The career hook (why you should care even if you hate policy)
Hereโs where your job search enters the room.
A national Alzheimerโs prophylaxis policy would create entirely new roles:
โข Genetic risk counselors for employers
โข โPre-diagnosisโ care coordinators in insurance
โข Compliance and ethics officers for at-risk data privacy
โข New training specialties for geriatric nurses, data scientists, and benefits managers
If you work in health tech, HR, benefits brokerage, pharma sales, or public policy โ this is a near-future skill set you can start building now. Ignoring it means competing against people who saw it coming.
What Iโm actually doing with this research
Iโm not just theorizing. My current writing outlines a state-level pilot framework that answers:
โข Who consents for a healthy person?
โข What happens if prophylaxis fails โ or has side effects?
โข How do employers handle โat riskโ designations without discrimination?
Iโll be sharing key sections over the next few weeks. First up: the liability question that keeps corporate counsel up at night.
Voltaire was right: the right question is more revealing than any tidy answer.
My question to you โ whether youโre in healthcare, tech, or just planning a 30-year career:
Are you waiting for Alzheimerโs prevention to become mainstream before you learn how it affects your job market?ย The framework is designed to be implementable at the primary care level โ no specialist required. I practice what I preach โ I’ve been following this framework myself for two years. The built-in design means that even if I was never at elevated risk, I’ve already realized measurable health and cost benefits. That’s the win-win.
Posted in
– ๐๐จ๐ฅ๐ญ๐๐ข๐ซ๐ย ย ย So hereโs my question: Should a national policy treat perfectly healthy, โat riskโ people for Alzheimerโs before they show a single symptom?
Iโve spent the last several months researching and writing exactly that โ a new national prophylaxis framework for Alzheimerโs prevention. Not early detection. Prevention before onset. [Spoiler alert: in June I will send the 1500-word policy proposal to Health Affairs]
The uncomfortable reality (why this is not academic)
Most healthcare policy waits for a diagnosis. My research flips the model: identify genetic, biomarker, or lifestyle-based risk in healthy individuals, then intervene with drugs, protocols, or monitoring.
The upside is obvious โ delaying or stopping Alzheimerโs entirely. The downside is less discussed: labeling healthy people as โpre-patients,โ potential over-medicalization, and a massive shift in who pays for what.
Whether you love or hate the idea, itโs coming. And that changes your industry.
The career hook (why you should care even if you hate policy)
Hereโs where your job search enters the room.
A national Alzheimerโs prophylaxis policy would create entirely new roles:
โข Genetic risk counselors for employers
โข โPre-diagnosisโ care coordinators in insurance
โข Compliance and ethics officers for at-risk data privacy
โข New training specialties for geriatric nurses, data scientists, and benefits managers
If you work in health tech, HR, benefits brokerage, pharma sales, or public policy โ this is a near-future skill set you can start building now. Ignoring it means competing against people who saw it coming.
What Iโm actually doing with this research
Iโm not just theorizing. My current writing outlines a state-level pilot framework that answers:
โข Who consents for a healthy person?
โข What happens if prophylaxis fails โ or has side effects?
โข How do employers handle โat riskโ designations without discrimination?
Iโll be sharing key sections over the next few weeks. First up: the liability question that keeps corporate counsel up at night.
Voltaire was right: the right question is more revealing than any tidy answer.
My question to you โ whether youโre in healthcare, tech, or just planning a 30-year career:
Are you waiting for Alzheimerโs prevention to become mainstream before you learn how it affects your job market?ย The framework is designed to be implementable at the primary care level โ no specialist required. I practice what I preach โ I’ve been following this framework myself for two years. The built-in design means that even if I was never at elevated risk, I’ve already realized measurable health and cost benefits. That’s the win-win.
Intrigued? The first installment drops next week.